OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacogenomics Journal is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus - a cohort study	52
Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach	40
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study	24
Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests	22
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis	21
Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial	21
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data	19
Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors	19
Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study	18
Clinical utility of pharmacogenetics in a psychiatric and primary care population	15
The expression level of Neuronal Calcium Sensor 1 can predict the prognosis of cytogenetically normal AML	15
Correction to: One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study	15
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis	14
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress	13
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population	12
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States	12
AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients	11
Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort	11
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application	11
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance	10
Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis	10
Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment of Slovenian patients undergoing kidney transplantation in the U-PGx PREPARE study	10
HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn’s disease patients	10
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform	10
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females	9

Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: a comprehensive analysis using Mendelian randomization, animal models, and transcriptomics	8
STRIPE partners in precision medicine series: pharmacist perspective	7
Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes	7
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)	7
Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors	7
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension	7
Cytochrome P450-2D6 activity in people with codeine use disorder	6
Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications	6
Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study	6
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study	6
Correction to: Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review	6
Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention	6
Genetic markers of early response to lurasidone in acute schizophrenia	6